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Abstract
Background: A few polymorphisms are located in the mature microRNA sequences. Such polymorphisms could directly
affect the binding of microRNA to hundreds of target mRNAs. It remains unknown whether rs4919510:C.G located in the
mature miR-608 alters breast cancer susceptibility.
Methods: The association of rs4919510:C.G with risk and pathologic features of breast cancer were investigated in two
independent case-control studies, the first set including 1,138 sporadic breast cancer patients (including 927 invasive ductal
carcinoma patients, 777 of them with known subtypes: 496 luminal-like, 133 HER2-positive, and 148 triple-negative) and
1,434 community-based controls, and the second set including 294 familial/early-onset breast cancer patients and 500
hospital-based cancer-free controls. Odds ratios (ORs) were estimated by logistic regression. Predicted targets of miR-608
and complementary sequences containing rs4919510:C.G were surveyed to reveal potential pathological mechanism.
Results: In the first set, although rs4919510:C.G was unrelated to breast cancer in general patients, variant genotypes (CG/
GG) were specifically associated with increased risk of HER2-positive subtype (Adjusted OR=1.97, 95% CI, 1.3422.90 in the
recessive model). Variant G-allele was the risk allele with OR of 1.62 (95% CI, 1.2322.15). Patients carrying GG-genotype also
had larger HER2-positive tumors (P for Kruskal-Wallis test=0.006). The relationship between rs4919510:C.G and risk of
HER2-positive subgroup was validated in the second set (Bonferroni corrected P=0.06). The adjusted combined OR (total
164 HER2-positive cases) in the recessive model was 1.97 (95% CI, 1.4322.72) for GG genotype (corrected P=1.1610
24).
Bioinformatic analysis indicated that, HSF1, which is required for HER2-induced tumorigenesis, might be a target of miR-608.
The minimum free-energy of ancestral-miR-608 (C-allele) binding to HSF1 is 235.9 kcal/mol, while that of variant-form (G-
allele) is 231.5 kcal/mol, indicating a lower affinity of variant-miR-608 to HSF1 mRNA.
Conclusion: rs4919510:C.G in mature miR-608 may influence HER2-positive breast cancer risk and tumor proliferation.
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Introduction
MicroRNAs (miRNAs) are an abundant class of small non-
protein-coding RNAsthat actasnegative gene-regulators. miRNAs
represent ideal candidates for cancer predisposition loci because
smallvariationinquantityhasaneffectonhundredseventhousands
of target mRNAs and might result in diverse functional con-
sequences [1,2]. A strong link between altered miRNAs, either in
structure or in quantity of mature product, and various cancer risks
has been established. Genetic variants such as single-nucleotide
polymorphisms (SNPs) and mutations may change the property of
miRNAs through altering miRNA expression and/or maturation.
The role of genetic variants in miRNAs or in miRNA-targeting
sites in breast cancer susceptibility has attracted much attention.
Several SNPs in the sequences of pre-miRNAs such as miR-196a2
(rs11614913:T.C), miR–499 (rs3746444:A.G), and miR-125a
(rs12975333:G.T) were associated with significantly increased
risks of breast cancer in some but not all studies [2,3,4].
Because SNPs located in the mature miRNA region could
directly affect the binding to target mRNAs, we focused on this
kind of SNPs for molecular epidemiological study. There are only
a few such SNPs according to bioinformatics survey (i.e.,
rs12975333 in miR-125a, rs4822739 in miR-548j, and
rs4919510 in miR-608). rs4919510:C.G in mature miR-608 is
of particular interests because it is predicted that its variant form
can bind with a different energy to its targets. For example, the
ancestral form of miR-608 binds its target within the insulin
receptor (INSR) mRNA with a gGo f224.04 kJ/mol, whereas its
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Moreover, the predicted targets of miR-608 include interleukin-1
alpha (IL1A), growth hormone receptor (GHR), and TP53 [5]. Of
note, INSR [6], IL1A [7], GHR [8], and TP53 [9] were reported
to be associated with breast cancer. Therefore, we hypothesized
that rs4919510:C.G in mature miR-608 might relate to breast
cancer. To test hypothesis, we genotyped this SNP and evaluated
its association with breast cancer risk as well as clinical features in
two independent case-control sets of Chinese women, totally
comprising 1,432 breast cancer cases and 1,934 cancer-free
controls.
Materials and Methods
Patients
In the first set, all the participants were genetically unrelated
Han Chinese women living in Shanghai City and its surrounding
areas [10]. The 1,138 patients had pathologically-confirmed
primary breast cancer and were consecutively recruited from the
Department of Breast Surgery at Fudan University Shanghai
Cancer Center (FUSCC) between January 2006 and December
2008. Participants with a previous history of cancer (except breast
cancer) and metastatic breast cancer were excluded. The 1,434
controls were from a community-based breast cancer screening
program as previously described [11]. All the controls were
determined as cancer-free after comprehensive examinations.
After finishing a written informed consent document, each
participant was carefully interviewed to obtain epidemiological
information and donated approximately 325 ml of peripheral
venous blood. Table 1 presents the characteristics of study
subjects. Cases and controls were comparable in age (both median
age was 49 years, P=0.761) and menopausal status (42%
postmenopausal in both groups, P=0.108). Compared with the
controls, more women in patient group had a family history of
first-degree relatives with breast cancer (2.7% versus 7.5%,
P=4.6610
28). Among the 1,138 cases, 927 (81.5%) were invasive
ductal carcinoma (IDC), 14.4% were ductal carcinoma in situ
(DCIS), and 4.1% were other special histological types. IDC was
classified as three subtypes according to the immunohistochemistry
(IHC) status of estrogen receptor (ER), progesterone receptor (PR),
and human epidermal growth factor receptor-2 (HER2). HER2
positivity was determined by IHC 3+ (HerceptTest, DAKO,
Denmark) or fluorescence in situ hybridization (FISH) positive
status (PathVysion HER2 DNA probe kit). Most of, but not all,
patients with equal HER2 protein expression (IHC 2+) were also
selected to have a FISH test for HER2 gene amplification. We
defined subtypes as following: luminal-like (ER+ and/or PR+ and
HER2-), triple-negative (ER-, PR-, and HER2-), and HER2+
(HER2+, regardless of ER/PR) [12].
We also validated our results in another independent population
with mainly familial/early-onset breast cancer cases. Since 2000,
FUSCC has conducted a multi-center hospital-based gene
mutation screening project in order to gain a full understanding
of the contribution of germ-line mutations of high-penetrance
genes to hereditary and early-onset breast cancer in the Han
Chinese population [13]. The eligibility criteria have been
described elsewhere [13]. All of the selected familial cases had
been tested for BRCA1/2, BRIP1, and PALB2 germline
mutations and no deleterious changes were found. Among all
the recruited patients, we screened the candidates for the
validation set using following criteria: 1, genetically unrelated
Han Chinese women living in Shanghai City and its surrounding
areas; 2, the pathology of tumor having been confirmed in the
Department of Pathology of our hospital; 3, having spare and high
quality DNA samples (most were available between 2006 and
2009) for genotyping. Finally, we selected 294 patients recruited
between 2006 and 2009 as cases of the second set, 218 of them
with available ER, PR, and HER2 status. The current study was
approved by the Ethics Committee of FUSCC and all patients
provided written informed consent. All clinical investigation had
been conducted according to the principles expressed in the
Declaration of Helsinki.
Genotyping
Genomic DNA was extracted from the blood leukocytes of the
participants using Gentra’s PureGene DNA Purification Kit
(Gentra systems, USA). Genotyping was done using the 12-plex
SNPstream system (Beckman Coulter, USA) at the Chinese
National Human Genome Center at Shanghai. Primers and
probe were: up, AAGATCCACTGGGCCAAG; low, AGG-
CAGCCTTTGATGGAA; probe, GCGGTAGGTTCCCGA-
CATATGGCCAGGGGTGGTGTTGGGACAGCT. To ensure
the reliability of the results, operators performing the genotyping
assays were unaware of the disease status of each sample, and each
batch of samples contained at least one positive control consisting
of DNA samples with known genotype and two negative controls
of pure water.
Bioinformatic Analysis
TargetScan Human 5.2 (http://www.targetscan.org/) and
MicroCosm Targets Version 5 (http://www.ebi.ac.uk/enright-
srv/microcosm/htdocs/targets/v5/) were employed to predict the
targets of miR-608. RNAfold (http://rna.tbi.univie.ac.at/) was
used to calculate the secondary structure of miR-608 stem-loop
sequence based on minimum free energy (MFE). RNAhybrid
(http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/) was used to
evaluate the affinity of variant miR-608 and ancestral miR-608 to
predicted targets, respectively.
Power Analysis
The program Quanto (http://hydra.usc.edu/gxe) was used to
estimate the statistical power. The variant allele frequency of miR-
608 (about 60% according to our genotyping results), odds ratio
(1.5 or 1.8), incidence of breast cancer in the studied population
(25 in 100,000 in Shanghai, China), and sample sizes were taken as
the parameters. For the first set, there were 1,138 overall cases,
927 IDC, 133 IDC with HER2+ subtype, accompanied by 1,434
controls. In the recessive model, the sample sizes had 99.9%,
99.5%, and 60% power to detect allele with OR of 1.5, and had
99.9%, 99.9%, and 89% power to detect allele with OR of 1.8, for
the overall cases, IDC, and HER2+ cases, respectively. In the
additive model, the sample sizes had 99.9%, 99.9%, and 85%
power to detect allele with OR of 1.5, and had 99.9%, 99.9%, and
99.0% power to detect allele with OR of 1.8, for the overall cases,
IDC, and HER2+ cases, respectively. For the second set, there
were 31 IDC with HER2+ subtype, accompanied by 500 controls.
In the recessive model, the sample sizes had only 20% power to
detect allele with OR of 1.5, and had 35% power to detect allele
with OR of 1.8, for the HER2+ cases. The power would be much
higher if we combined the first and the second set together. All the
tests of power calculation were two-sided.
Statistical Analysis
Comparison between groups used x
2 test for categorical
variables. Student’s t-test and Kruskal-Wallis test were used to
compare continuous variables among two and more than two
groups, respectively. Hardy-Weinberg equilibrium (HWE) was
MicroRNA-608 and Risk of HER2+ Breast Cancer
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2 tests. The multiple comparison P-values were
corrected by Bonferroni correction. Odds ratio (OR) adjusted
for age, age at menarche, menopause status, body mass index
(BMI) and family history of breast cancer, along with 95%
confidence interval (CI), were determined by logistic regression. A
two-sided P-value #0.05 was considered statistically significant.
Statistical analysis was performed using STATA v.10.0 and SPSS
v.12.0.
Results
In both study sets, genotype distributions of rs4919510:C.Gi n
the controls was in agreement with HWE. The frequency of
variant G-allele was about 57% in this study, in consistent with
genotyping data in NCBI-dbSNP and HapMap database of
Chinese population. In the first set, there was no association
between rs4919510:C.G and breast cancer risk either in the
overall cases or in the IDC cases (Table S1). In the sub-analysis
according to the IHC-based breast cancer subtypes (Table 2),
although we did not observe any significant relationship between
rs4919510:C.G and luminal-like or triple-negative subtype,
a remarkable increase in risk of HER2+ subtype (n=133) was
found in women carrying variant genotypes (CG/GG) in a dose-
effect manner (Bonferroni corrected P of 3.6610
23 for trend, and
of 9.3610
24 for heterogeneity). Variant G-allele was the risk allele
(OR=1.62; 95% CI, 1.2322.15) compared with its ancestral C-
allele. Table 3 shows the results of multivariate analysis.
rs4919510:C.G was independently related to HER2+ breast
cancer risk in the dominant model (OR=2.10, 95% CI, 1.15–
3.82), recessive model (OR=1.97, 95% CI, 1.3422.90), as well as
additive model (CG vs. CC, OR=1.63 with 95% CI of
0.8723.08; GG vs. CC, OR=2.87 with 95% CI of 1.5225.42;
overall P=0.001).
Table 1. Summary characteristics of the participants in the first set.
Cases (n=1,138) Controls (n=1,434) P
Age (median) 49 years 49 years 0.761
Age at menarche (median) 15 years 16 years 0.020
BMI (mean) 23.6 23.2 0.073.
Menopause (%) Premenopausal 647 (57.9) 1055 (59.1) 0.108
Postmenopausal 471 (42.1) 731 (41.9)
Unknown 20 148
Family history of breast
cancer (%)
No 1,044 (92.5) 1,301 (97.3) 4.6610
28
Yes 84 (7.5) 36 (2.7)
Unknown 10 97
Histology (%) DCIS 164 (14.4) N.A. N.A.
Others 47 (4.1) N.A. N.A.
IDC 927 (81.5) N.A. N.A.
ER Negative 231 (29.7)
Positive 548 (70.3)
Unknown 148
PR Negative 273 (35.1)
Positive 504 (64.9)
Unknown 150
HER2 Negative 645 (82.9)
Positive 133 (17.1)
Unknown 149
Subtype Luminal-like 496 (63.8)
HER2+ 133 (17.2)
Triple-negative 148 (19.0)
Unknown 150
Lymph nodes Negative 411 (57.1)
Positive 309 (42.9)
Unknown 207
Size T1 414 (51.4)
T2 353 (43.8)
T3-4 39 (4.8)
Unknown 121
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; N.A., not applicable.
doi:10.1371/journal.pone.0035252.t001
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the breast tumor development. Analogously, rs4919510:C.G was
unrelated to either tumor size (reflecting local tumor proliferation)
or lymph nodes status (reflecting tumor dissemination and
metastasis potentials) in the overall IDC, luminal-like subgroup,
or triple-negative subgroup (Table S2). However, there was an
incremental risk of high stage of tumor size (T2-4 vs T1) in patients
carrying variant homozygous genotypes of rs4919510:C.G in the
HER2+ cases (P for heterogeneity=0.017, P for trend=0.004). If
we treat the tumor size as a continuous variable, we still found that
Table 3. Multivariate analysis of risk for HER2-positive breast cancer of 1,567 subjects in the first set.
Characteristics P OR 95% CI
Age (continuous)
# 0.26 0.98 0.95 to 1.01
Age at menarche (continuous)
# 0.0004 0.81 0.72 to 0.91
Menopausal status Pre. vs. Post. 0.042 1.91 1.02 to 3.57
BMI (continuous)
# 0.009 1.09 1.02 to 1.17
Family history of breast cancer No vs Yes 0.003 3.14 1.49 to 6.65
Genotype of rs4919510 in miR-608 Additive
*
CC 1 (Reference)
CG 0.13 1.63 0.87 to 3.08
GG 0.001 2.87 1.52 to 5.42
Dominant (CC versus CG+GG) 0.016 2.10 1.15 to 3.82
Recessive (CC+CG versus GG) 0.001 1.97 1.34 to 2.90
BMI, body mass index; OR, odds ratio; CI, confidence interval.
*the overall P value is 0.001 for the additive model.
#for continuous variables, younger age at menarche and higher BMI are risk.
OR and 95% CI calculated by logistic regression, adjusted for age, age at menarche, menopausal status, BMI, and family history of breast cancer. CC genotype is as
reference in the additive and dominant model, CC+CG genotype as reference in the recessive model. Additive model, dominant model, and recessive model are tested
respectively. The P-values and ORs with 95% CIs of co-variables are from logistic regression with additive model of rs4919510.
doi:10.1371/journal.pone.0035252.t003
Table 4. Associations between rs4919510:C.G and HER2-positive breast cancer subtype in the IDC cases in combined sets
(n=3,366).
rs4919510 The Second Set (control, n=500; cases, n=294) Combined Sets (controls, n=1,934; cases, n=1,432)
Ctls
(n=500)
HER2+
Cases
(n=31) OR P
#/P
*
Ctls
(n=1,934)
HER2+ Cases
(n=164) OR P
#/P
*
n% n % n % n %
Additive CC 77 15.7 2 6.5 Ref. 0.06/0.18 354 18.6 18 11.0 Ref. 1.1610
–4/
3.3610
24
CG 230 46.8 11 35.5 1.84
(0.39217.43)
0.02
&/0.06
& 914 47.9 65 39.6 1.42
(0.8322.43)
1
3.2610
–5&/
9.6610
–5&
GG 184 37.5 18 58.0 3.77
(0.86234.14)
640 33.5 81 49.4 2.49
(1.45–4.48)
1
Dominant CC 77 15.7 2 6.5 Ref. 0.16/0.48 354 18.6 18 11.0 Ref. 0.014/0.042
CG+GG 414 84.3 29 93.5 2.70
(0.66223.76)
1554 81.4 146 89.0 1.88
(1.1423.12)
1
Recessive CC+CG 307 62.5 13 41.9 Ref. 0.02/0.06 1268 66.5 83 50.6 Ref. 3.5610
–5/
1.1610
–4
GG 184 37.5 18 58.1 2.31
(1.0425.25)
640 33.5 81 49.4 1.97
(1.4322.72)
1
Allele C 384 39.1 15 24.2 Ref. 0.02/0.06 1622 42.5 101 30.8 Ref. 3.6610
–5/
1.1610
24
G 598 60.9 47 75.8 2.01
(1.0923.93)
2194 57.5 227 69.2 1.66
(1.3022.14)
Ctls controls; IDC, invasive ductal carcinoma.
#P for heterogeneity.
&P for trend.
*P values after Bonferroni correction (by 63).
1OR adjusted for study cohort.
doi:10.1371/journal.pone.0035252.t004
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e35252Figure 1. Bioinformatics prediction of rs4919510 within miR-608 and schematic representation of potential pathological
mechanism of rs4919510 in HER2-positive breast cancer development. A, the predicted secondary structure of human miR-608 stem-loop
sequence (100 bp) by RNAfold, with either the C- allele or G-allele. For ancestral form with C-allele, the optimal secondary structure with a minimum
free energy (MFE) of 232.20 kcal/mol. The frequency of the MFE structure in the ensemble is 0.53%, and the ensemble diversity is 13.52. For the
variant form, the optimal secondary structure with the same MFE of 232.20 kcal/mol. The frequency of the MFE structure is 0.33%, and the ensemble
diversity is 14.09. The structure plot shows that variant G-allele strongly interfere with loop forming. B, HSF1 is a predicted target of miR-608 and
rs4919510:C.G is just located at the complementary sequence. Asterisk indicates the polymorphic site. The plot of predicted duplex formation is
from MicroCosm Targets website. C, Predicted secondary structure of duplex formation between miR-608 and 39UTR of HSF1 by RNAhybrid.
rs4919510:C.G changes the MFE, with ancestral form of 235.9 kcal/mol and variant form of 231.5 kcal/mol. D, schematic representation of
speculated pathological mechanism of rs4919510 in HER2-positive breast cancer development. In this model, miR-608 harbouring the rs4919510-C
allele (ancestral form) is set as the baseline condition. The C-to-G substitution might weaken the suppression of HSF1 mRNA by miR-608, leading to
relatively high expression of HSF1 protein and, in turn, up-regulating HSPs and facilitating HER2-expressing normal or precancerous breast cells to
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compared with those carrying CC or CG (Overall P for
Kruskal-Wallis test=0.006; P-values for Dunn’s Multiple Com-
parison test of CC vs GG or CG vs GG were all ,0.05, Figure
S1).
To validate our findings in the first set, we performed another
independent case-control study involving 294 familial/early-onset
breast cancer cases and 500 hospital-based cancer-free controls.
Similar to the first study, there was no fundamentally different
result in the second set, which showed that GG genotype was
associated with an increased risk of HER2-positive breast cancer,
with unadjusted P value of 0.02 and corrected P value of 0.06. The
associations were more significant when the two studies were
combined together (total number of HER2+ cases were 164), with
a crude P value of 3.6610
–5 for the G allele. After conservative
Bonferroni correction, rs4919510:C.G was still significantly
associated with increased risk of HER2-positive breast cancer
(Table 4).
In order to reveal the potential genetic and molecular
mechanism of epidemiological observation, we subsequently
conducted bioinformatic analysis. First, we predicted the second-
ary structure of variant and ancestral miR-608 stem-loop
sequence, respectively. Though the optimal secondary structure
of the two forms had the same MFE of –32.2 kcal/mol, the free
energy of the thermodynamic ensemble, frequency of MFE
structure in the ensemble, and ensemble diversity were all changed
(Figure 1A). Using MicroCosm Targets and TargetScan tools,
963 and 189 targets of miR-608 were identified respectively. We
scrutinized all the candidate transcripts and found nine targeting
transcripts closely related to breast carcinogenesis and progression
according to current literature. Among them, miR-608 might bind
to the 39 untranslated regions (39UTR) at the complementary
sequence containing polymorphic site of rs4919510:C.G in two
transcripts, one was heat shock transcription factor-1 (HSF1)
(Figure 1B) and the other was lymphocyte-specific protein-1
(LSP1). Since the current literature suggested an association of
HER2+ breast cancer with HSF1 but not with LSP1, we further
analyzed the differential affinity of variant and ancestral miR-608
to the 39UTR of HSF1. The MFE of ancestral miR-608 binding to
HSF1 was 235.9 kcal/mol, while that of variant form was
231.5 kcal/mol, indicating a lower affinity of variant miR-608 to
the binding sites in HSF1 39UTR (Figure 1C).
Discussion
In this study, we for the first time reported that variant genotype
of rs4919510:C.G located in mature miR-608 was associated
with significantly increased risk of HER2+ breast cancer but not
other subtypes. Although the significant association between
rs4919510:C.G and HER2+ breast cancer was observed in the
stratified population, the power analysis demonstrated that the
current sample size has 85% power to identify allele with OR of
1.5 in the additive model. Univariate and multivariate analyses
consistently showed a risk role of rs4919510 G-allele for HER2+
subtype. More importantly, we validated the findings in a second
independent population with a borderline significance. It was
likely that the relatively small sample size of the second study made
a borderline significant. When we combined the two sets together,
G allele and GG genotype were more significantly associated with
increased risk of HER2-positive breast cancer even after
conservative Bonferroni correction. We believe our observed
association is likely true rather than false positive.
To identify breast cancer-related mRNA targeted by miR-608,
we surveyed the predicted transcripts. Among them, two
transcripts (HSF1 and LSP1) were predicted to bind miR-608 at
the polymorphic site of rs4919510:C.G. HSF1 is of particular
interests because it is recently proven to be required for HER2-
induced tumorigenesis and HER2-expressing cell proliferation.
The potential mechanism is likely that HSF1 maintains levels of
heat shock proteins (HSPs) such as HSP72 and HSP27 [14]. On
the other hand, HER2 can activate HSF1 by increasing HSF1
trimer formation and promoting HSF1 protein synthesis [15]. It
seems there is a synergistic loop between HER2 and HSF1, and
slight changes in HSF1 level (regulated by rs4919510:C.Gi n
miR-608) might be amplified by the loop, resulting in more
significant alterations in HSF1/HSPs level and consequently
facilitating pathological outcomes such as HER2+ breast cancer
transformation and proliferation (illustrated in Figure 1D). The
outcomes of in silico analysis and theoretical deduction well explain
the epidemiological observations. In addition, bioinformatic
analysis has also showed LSP1 mRNAs might be targeted by
miR-608 and rs4919510:C.G is exactly located at the binding
sites. LSP1 is reported as a susceptibility locus of breast cancer in
genome-wide association studies [16,17]. However, it is not found
to be associated with HER2+ subtype [18] and its exact role in
HER2+ breast cancer development remains to be investigated.
The limitation of this study should be acknowledged. First,
when we compared the controls from the first set with those from
the second set, there was a significant difference between the two
control population (in additive model, CC vs GC vs GG:
P=0.046; in recessive model, CC+GC vs GG: P=0.032). These
two sets were genotyped using the same genotyping platform and
comparable technical procedure. Therefore, the observed differ-
ence might be caused by the population heterogeneity between the
two control sets. The first control set was from a community-based
breast cancer screening program, while the second set was from
the hospital-based female population (main from the Department
of Breast Surgery). Since most women came to our hospital for
cancer screening as well as dealing with benign breast disease, the
enrolled control women in the second set could have a higher
prevalence of benign breast disease. Of note, HSF1, a predicted
target of miR-608, has been proved to be associated with cell
proliferation. It is reasonable to conjecture that the higher
proportion of G-allele in the hospital-based controls compared
with the community-based controls is probably due to the
pathological effect of rs4919510:C.G on benign breast disease.
In other word, rs4919510:C.G in miR-608 might participate in
the whole procedure of normal cell proliferation, preneoplasia
formation, and cancer initiation. Of course, this issue is beyond the
current scope of this article and needs further investigation.
Second, although we have investigated two study cohorts including
reasonable sample sizes, due to rare frequency of HER2+ breast
cancer, the sample size is quite small (in the first set, n=133; in the
second set, n=31) for the investigation of HER2+ breast cancer
specific risk effects. The power calculation for the second set also
indicated that the validation samples had a low power of 20235%
to identify a true association between risk of HER2+ subtype
transform cancer cells. HSPs also promote tumor cell proliferation. After cancer evolutionary selection, HER2-overexpressed or HER2-amplified tumor
is formed since HER2+ cells are easy to survive under HSF1/HSPs stimulating. Moreover, overexpression of HER2 would activate HSF1 and promote
HSF1 protein synthesis, further upregulating HSPs and facilitating tumorigenesis and development of HER2+ breast cancer.
doi:10.1371/journal.pone.0035252.g001
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of G-allele at 1.5–1.8.
In summary, we identified that rs4919510:C.G in mature
sequence of miR-608 may affect breast cancer risk and influence
tumor proliferation. It is speculated that differential regulations of
HSF1 mRNA by variant and ancestral miR-608 result in the
differential HSF1 levels, leading to differential development of
HER2+ breast cancer. Further replication studies of our findings
with diverse ethnic groups and functional characterization of
rs4919510:C.G variant in miR-608 are warranted.
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